Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRP-5051 in DMD amenable to exon 51 skipping
NCT03375255Phase 1Completed
- Sponsor
- Sarepta Therapeutics
- Start
- Feb 2018
- Primary completion
- Aug 2019
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of Vesleteplirsen in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Primary endpoint: Number of Participants with Adverse Events (AEs) up to 14 weeks. Started Feb 2018; status: completed.
02
Drugs
Vesleteplirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03375255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03375255.